Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FPR1 | P21462 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850584 | 0.91 | SIGMAR1 (0.35) | SIGMAR1ALDH1A1LMNACYP17A1CYP19A1 | |
| SCHEMBL4061204 | 0.83 | SIGMAR1 (0.34) | SIGMAR1EPHX2 | |
| SCHEMBL5736685 | 0.80 | SIGMAR1 (0.34) | SIGMAR1EPHX2 | |
| SCHEMBL2848151 | 0.70 | — | — | |
| SCHEMBL15660455 | 0.69 | FAAH (0.39) | EPHX2ALDH1A1FAAHFPR1P2RX7 | |
| SCHEMBL2011805 | 0.67 | FAAH (0.38) | EPHX2ALDH1A1FAAHFPR1P2RX7 | |
| SCHEMBL28531066 | 0.66 | SIGMAR1 (0.45) | SIGMAR1EPHX1EPHX2ALDH1A1KMT2A | |
| SCHEMBL5471270 | 0.65 | GRIN2D (0.31) | — | |
| SCHEMBL6109500 | 0.65 | FAAH (0.39) | EPHX1EPHX2ALDH1A1FAAHLMNA | |
| SCHEMBL11447336 | 0.64 | EPHX1 (0.45) | SIGMAR1EPHX1EPHX2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802185-B2 | Catalyst system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2017-10-31 | — | — | US | disclosed |
| US-20150321186-A1 | CATALYST SYSTEM | Mitsubishi Chemical UK Limited (GB) | 2015-11-12 | — | — | US | disclosed |
| EP-2243549-A1 | A catalyst system | Lucite International UK Limited (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-7371705-B2 | Phospha-adamantane(s) catalytic system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2008-05-13 | — | — | US | disclosed |
| EP-1713582-A1 | A CATALYST SYSTEM | Lucite International UK Limited (GB) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005079981-A1 | A CATALYST SYSTEM | LUCITE INTERNATIONAL UK LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| EP-1534427-A1 | AN ADAMANTYL CATALYTIC SYSTEM | Lucite International UK Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004014552-A1 | A PHOSPHA-ADAMANTANE (S) CATALYTIC SYSTEM | LUCITE INTERNATIONAL UK LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150321186-A1 | CATALYST SYSTEM | SMS, COASY, ABCB7 | SIGMAR1 3491/4885EPHX1 945/4885EPHX2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.